Assessment of doripenem, meropenem, and imipenem against respiratory isolates of Pseudomonas aeroginosa in a tertiary care hospital of north India
Author:
Publisher
Jaypee Brothers Medical Publishing
Subject
Critical Care and Intensive Care Medicine
Link
https://www.ijccm.org/doi/pdf/10.4103/ijccm.IJCCM_341_17
Reference18 articles.
1. 1. Hu YF, Liu CP, Wang NY, Shih SC.In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. BMC Infect Dis 2016;16:444.
2. 2. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. J Antimicrob Chemother 2014;69:1804-14.
3. 3. Wolter DJ, Lister PD. Mechanisms of ß-lactam resistance among Pseudomonas aeruginosa. Curr Pharm Des 2013;19:209-22.
4. 4. Luyt CE, Aubry A, Lu Q, Micaelo M, Bréchot N, Brossier F, et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014;58:1372-80.
5. 5. Bretonnière C, Jacqueline C, Caillon J, Guitton C, Le Mabecque V, Miégeville AF, et al. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem. J Antimicrob Chemother 2010;65:2423-7.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Approaches to enhance the antimicrobial activity of carbapenems within bacterial biofilms;RSC Pharmaceutics;2024
2. In vitro activities of ceftazidime–avibactam, ceftolozane–tazobactam, meropenem–vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012–2021;International Journal of Antimicrobial Agents;2023-08
3. Reversal of carbapenem resistance inPseudomonas aeruginosaby camelid single domain antibody fragment (VHH) against the C4 dicarboxylate transporter;2023-06-22
4. Antibacterial efficacy of silver nanoparticles (AgNPs) against metallo-β-lactamase and extended spectrum β-lactamase producing clinically procured isolates of Pseudomonas aeruginosa;Scientific Reports;2022-11-30
5. Seeking patterns of antibiotic resistance in ATLAS, an open, raw MIC database with patient metadata;Nature Communications;2022-05-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3